PEDIATRICS Vol. 79 No. 6 June 1987, pp. 869-873
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Woods, W. G.
Right arrow Articles by Tuchman, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Woods, W. G.
Right arrow Articles by Tuchman, M.

Neuroblastoma: The Case for Screening Infants in North America

William G. Woods MD1 and Mendel Tuchman MD1

1 From the Divisions of Oncology and Metabolism, Department of Pediatrics, University of Minnesota Hospital, Minneapolis

Neuroblastoma is a disease in which easily measured tumor markers are excreted. It is curable when diagnosed in an early stage and at an early age, and it has a high incidence relative to other serious childhood diseases. Recent advances in screening infants for neuroblastoma by detection of urinary homovanillic acid and vanillylmandelic acid, the most useful markers of neuroblastoma, are described. Based on results from Japan's mass-screening program and on the authors' observations, it is estimated that mass screening for neuroblastoma could save 260 lives annually in the United States.

Key Words: neuroblastoma • solid tumor • mass screening • homovanillic acid • vanillylmandelic acid

Submitted on June 23, 1986
Revised on August 1, 1986




This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
L. Soderstrom, W. G. Woods, M. Bernstein, L. L. Robison, M. Tuchman, and B. Lemieux
Health and Economic Benefits of Well-Designed Evaluations: Some Lessons From Evaluating Neuroblastoma Screening
J Natl Cancer Inst, August 3, 2005; 97(15): 1118 - 1124.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. G. Woods
Substitute "Prostate Cancer" for "Neuroblastoma"?
J. Clin. Oncol., March 1, 2002; 20(5): 1154 - 1155.
[Full Text] [PDF]